OKUR
OnKure Therapeutics, Inc.
NASDAQ: OKUR · HEALTHCARE · BIOTECHNOLOGY
$3.44
-12.02% today
Updated 2026-05-11
Market cap
$157.95M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.32
Dividend yield
—
52W range
$2 – $5
Volume
0.3M
OnKure Therapeutics, Inc. (OKUR) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | $37000.00 | $50000.00 | $529000.00 | $560000.00 | $662000.00 | $830000.00 |
| Gross profit | $-37000.00 | $-50000.00 | $-529000.00 | $-560000.00 | $-662000.00 | $-830000.00 |
| Gross margin | — | — | — | — | — | — |
| R&D | $15.91M | $28.12M | $25.86M | $32.12M | $43.80M | $48.26M |
| SG&A | — | — | $3.90M | $4.82M | $10.59M | $14.69M |
| Operating income | $-19.55M | $-39.82M | $-29.77M | $-36.93M | $-54.39M | $-62.95M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-19.43M | $-39.72M | $-29.38M | $-34.75M | $-51.71M | $-62.12M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-19.46M | $-39.77M | $-29.77M | $-35.31M | $-52.37M | $-62.95M |
| Interest expense | — | — | — | $0.00 | $300000.00 | $8000.00 |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-19.46M | $-39.77M | $-29.51M | $-35.31M | $-52.67M | $-59.52M |
| Net income growth (YoY) | — | -104.3% | +25.8% | -19.6% | -49.2% | -13.0% |
| Profit margin | — | — | — | — | — | — |